Edward Kim, MD, MBA, City of Hope National Medical Center
Articles by Edward Kim, MD, MBA, City of Hope National Medical Center
Edward S. Kim, MD, MBA, discusses the clinical implications of antibody-drug conjugates in HER2-positive solid tumors.
NSCLC: Final Thoughts
ByBen Levy, MD, The Johns Hopkins University School of Medicine,Melissa Johnson, MD, Tennessee Oncology,Edward Kim, MD, MBA, City of Hope National Medical Center,Jacob Sands, MD, Dana-Farber Cancer Institute,Alexander Spira, MD, PhD, FACP, Virginia Cancer Specialists, US Oncology The discussion about the evolution of precision medicine in non–small cell lung cancer (NSCLC) ends as each expert discusses their final thoughts.
NSCLC: Overcoming Challenges
ByBen Levy, MD, The Johns Hopkins University School of Medicine,Melissa Johnson, MD, Tennessee Oncology,Edward Kim, MD, MBA, City of Hope National Medical Center,Jacob Sands, MD, Dana-Farber Cancer Institute,Alexander Spira, MD, PhD, FACP, Virginia Cancer Specialists, US Oncology Oncology experts provide insight on screening methods available and discuss strategies that may address challenges in identification of targetable mutations/tumor profiles in non–small cell lung cancer (NSCLC).
ROS1-Rearranged NSCLC: Updates FromASCO
ByBen Levy, MD, The Johns Hopkins University School of Medicine,Melissa Johnson, MD, Tennessee Oncology,Edward Kim, MD, MBA, City of Hope National Medical Center,Jacob Sands, MD, Dana-Farber Cancer Institute,Alexander Spira, MD, PhD, FACP, Virginia Cancer Specialists, US Oncology An overview of TKIs in ROS1-rearranged non–small cell lung cancer (NSCLC) and updated trial results that were presented at the American Society of Clinical Oncology (ASCO) 2021 annual meeting.
Preferred Treatment for ALK-Rearranged NSCLC
ByBen Levy, MD, The Johns Hopkins University School of Medicine,Melissa Johnson, MD, Tennessee Oncology,Edward Kim, MD, MBA, City of Hope National Medical Center,Jacob Sands, MD, Dana-Farber Cancer Institute,Alexander Spira, MD, PhD, FACP, Virginia Cancer Specialists, US Oncology Experts have a discussion about their preferred treatment approach for newly diagnosed ALK-rearranged non–small cell lung cancer (NSCLC).
ALK-Rearranged NSCLC: Updates From ASCO
ByBen Levy, MD, The Johns Hopkins University School of Medicine,Melissa Johnson, MD, Tennessee Oncology,Edward Kim, MD, MBA, City of Hope National Medical Center,Jacob Sands, MD, Dana-Farber Cancer Institute,Alexander Spira, MD, PhD, FACP, Virginia Cancer Specialists, US Oncology A summary of recent data that were presented at the American Society of Clinical Oncology (ASCO) 2021 annual meeting for ALK-rearranged non–small cell lung cancer (NSCLC).
RET-Fusions in NSCLC: Updates From ASCO
ByBen Levy, MD, The Johns Hopkins University School of Medicine,Melissa Johnson, MD, Tennessee Oncology,Edward Kim, MD, MBA, City of Hope National Medical Center,Jacob Sands, MD, Dana-Farber Cancer Institute,Alexander Spira, MD, PhD, FACP, Virginia Cancer Specialists, US Oncology An overview of the RET-fusion data updates that were presented at the American Society of Clinical Oncology (ASCO) 2021 annual meeting in non–small cell lung cancer (NSCLC).
Recent FDA-Approvals: MET Exon 14 Mutations in NSCLC
ByBen Levy, MD, The Johns Hopkins University School of Medicine,Melissa Johnson, MD, Tennessee Oncology,Edward Kim, MD, MBA, City of Hope National Medical Center,Jacob Sands, MD, Dana-Farber Cancer Institute,Alexander Spira, MD, PhD, FACP, Virginia Cancer Specialists, US Oncology An expert in non–small cell lung cancer (NSCLC) provides an overview of recent data presented at the American Society of Clinical Oncology 2021 annual meeting to treat MET exon 14 mutations.
Recent FDA-Approvals: HER2-Mutated NSCLC
ByBen Levy, MD, The Johns Hopkins University School of Medicine,Melissa Johnson, MD, Tennessee Oncology,Edward Kim, MD, MBA, City of Hope National Medical Center,Jacob Sands, MD, Dana-Farber Cancer Institute,Alexander Spira, MD, PhD, FACP, Virginia Cancer Specialists, US Oncology Edward Kim, MD, MBA, summarizes recent data for HER2-mutated in non–small cell lung cancer (NSCLC) presented at the American Society of Clinical Oncology 2021 annual meeting.
NSCLC: Sotorasib in Practice
ByBen Levy, MD, The Johns Hopkins University School of Medicine,Melissa Johnson, MD, Tennessee Oncology,Edward Kim, MD, MBA, City of Hope National Medical Center,Jacob Sands, MD, Dana-Farber Cancer Institute,Alexander Spira, MD, PhD, FACP, Virginia Cancer Specialists, US Oncology Experts share their real-world experiences regarding treatment with sotorasib, a new FDA-approved option for KRAS G12C-mutated non–small cell lung cancer (NSCLC).
Recent FDA-Approvals: KRAS G12C-Mutated NSCLC
ByBen Levy, MD, The Johns Hopkins University School of Medicine,Melissa Johnson, MD, Tennessee Oncology,Edward Kim, MD, MBA, City of Hope National Medical Center,Jacob Sands, MD, Dana-Farber Cancer Institute,Alexander Spira, MD, PhD, FACP, Virginia Cancer Specialists, US Oncology An overview of new data presented at the American Society of Clinical Oncology 2021 annual meeting for KRAS G12C-mutated non–small cell lung cancer (NSCLC).
ASCO 2021: New Data for NSCLC Treatment Options
ByBen Levy, MD, The Johns Hopkins University School of Medicine,Melissa Johnson, MD, Tennessee Oncology,Edward Kim, MD, MBA, City of Hope National Medical Center,Jacob Sands, MD, Dana-Farber Cancer Institute,Alexander Spira, MD, PhD, FACP, Virginia Cancer Specialists, US Oncology Jacob Sands, MD, reviews data regarding the investigational oral EGFR inhibitor DZD9008 that were presented at the American Society of Clinical Oncology (ASCO) 2021 annual meeting for the treatment of non–small cell lung cancer (NSCLC).
NSCLC: EGFR Exon 20 Insertion Treatment Options
ByBen Levy, MD, The Johns Hopkins University School of Medicine,Melissa Johnson, MD, Tennessee Oncology,Edward Kim, MD, MBA, City of Hope National Medical Center,Jacob Sands, MD, Dana-Farber Cancer Institute,Alexander Spira, MD, PhD, FACP, Virginia Cancer Specialists, US Oncology Experts provide an overview of treatment options for exon 20 insertion EGFR mutations in non–small cell lung cancer (NSCLC) and trial updates presented at the American Society of Clinical Oncology 2021 annual meeting .
Implications of Novel NSCLC Targeted Therapies
ByBen Levy, MD, The Johns Hopkins University School of Medicine,Melissa Johnson, MD, Tennessee Oncology,Edward Kim, MD, MBA, City of Hope National Medical Center,Jacob Sands, MD, Dana-Farber Cancer Institute,Alexander Spira, MD, PhD, FACP, Virginia Cancer Specialists, US Oncology An expert in non–small cell lung cancer (NSCLC) provides an overview of recent data presented at the American Society of Clinical Oncology 2021 annual meeting to treat MET exon 14 mutations.
Novel Therapies for NSCLC
ByBen Levy, MD, The Johns Hopkins University School of Medicine,Melissa Johnson, MD, Tennessee Oncology,Edward Kim, MD, MBA, City of Hope National Medical Center,Jacob Sands, MD, Dana-Farber Cancer Institute,Alexander Spira, MD, PhD, FACP, Virginia Cancer Specialists, US Oncology Edward Kim, MD, MBA, summarizes recent data for HER2-mutated in non–small cell lung cancer (NSCLC) presented at the American Society of Clinical Oncology 2021 annual meeting.
NSCLC: FLAURA Trial Results
ByBen Levy, MD, The Johns Hopkins University School of Medicine,Melissa Johnson, MD, Tennessee Oncology,Edward Kim, MD, MBA, City of Hope National Medical Center,Jacob Sands, MD, Dana-Farber Cancer Institute,Alexander Spira, MD, PhD, FACP, Virginia Cancer Specialists, US Oncology Edward Kim, MD, briefly summarizes results from the FLAURA trial in the treatment of previously untreated EGFR+ advanced non–small cell lung cancer (NSCLC).
First Generation TKIs in NSCLC
ByBen Levy, MD, The Johns Hopkins University School of Medicine,Melissa Johnson, MD, Tennessee Oncology,Edward Kim, MD, MBA, City of Hope National Medical Center,Jacob Sands, MD, Dana-Farber Cancer Institute,Alexander Spira, MD, PhD, FACP, Virginia Cancer Specialists, US Oncology Melissa Johnson, MD, provides an overview of other first generation TKIs for the treatment of non–small cell lung cancer (NSCLC) in the adjuvant setting.
ADAURA Trial Results and NSCLC Treatment Decisions
ByBen Levy, MD, The Johns Hopkins University School of Medicine,Melissa Johnson, MD, Tennessee Oncology,Edward Kim, MD, MBA, City of Hope National Medical Center,Jacob Sands, MD, Dana-Farber Cancer Institute,Alexander Spira, MD, PhD, FACP, Virginia Cancer Specialists, US Oncology Experts discuss how results from the ADAURA trial may influence treatment decisions in the adjuvant setting of non–small cell lung cancer (NSCLC).
NSCLC: ADAURA Trial Results
ByBen Levy, MD, The Johns Hopkins University School of Medicine,Melissa Johnson, MD, Tennessee Oncology,Edward Kim, MD, MBA, City of Hope National Medical Center,Jacob Sands, MD, Dana-Farber Cancer Institute,Alexander Spira, MD, PhD, FACP, Virginia Cancer Specialists, US Oncology Ben Levy, MD, leads a discussion about the evolution of precision medicine in non–small cell lung cancer (NSCLC) beginning with an overview of the results from the ADAURA trial.
ROS1-Rearranged NSCLC: Updates FromASCO
RET-Fusions in NSCLC: Updates From ASCO
NSCLC: FLAURA Trial Results
ALK-Rearranged NSCLC: Updates From ASCO
NSCLC: ADAURA Trial Results
Preferred Treatment for ALK-Rearranged NSCLC